No Data
No Data
Walvax Biotechnology Co., Ltd. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Walvax Biotechnology Co., Ltd. (SZSE:300142) missed earnings with its latest first-quarter results, disappointing overly-optimistic forecasters. The analysts look to have been far too optimistic
Watson Biotech (300142.SZ): Quarterly report to be disclosed on April 25
Gelonghui, April 23 | Watson Biotech (300142.SZ) said on the investor interactive platform that the company will disclose the 2024 quarterly report on April 25, 2024. For specific operating data, please refer to the regular report disclosed later.
Watson Biotech (300142.SZ): Currently, the company's RQ3033 vaccine is actively applying for approval for marketing
Gelonghui, April 18 | Watson Biotech (300142.SZ) said on the investor interactive platform that currently the company's RQ3033 vaccine is actively applying for approval for listing (including conditional listing), but the exact timing is subject to regulatory approval. The company continues to monitor the mutation of the coronavirus strain and promotes the development of iterative products through immunogenic bridging and other methods in accordance with the overall deployment of the country. If approved for listing in the future (including conditional listing), it is expected to have a positive impact on the company's business performance.
Investors Can Find Comfort In Walvax Biotechnology's (SZSE:300142) Earnings Quality
The market for Walvax Biotechnology Co., Ltd.'s (SZSE:300142) shares didn't move much after it posted weak earnings recently. We think that the softer headline numbers might be getting counterbalance
Watson Biotech (300142.SZ): The repurchase was completed and the total cost was 72.197,800 yuan to repurchase 2 million shares
Gelonghui, April 3, 丨 Watson Biotech (300142.SZ) announced that the actual time period for the company to repurchase shares is from April 7, 2023 to April 3, 2024. As of April 3, 2024, the total number of shares repurchased by the company through centralized bidding transactions through a dedicated securities account was 2 million shares, accounting for 0.12% of the company's total share capital. The highest transaction price was 36.28 yuan/share, the lowest transaction price was 35.69 yuan/share, and the total transaction amount was 72.1978 million yuan (excluding transaction fees). The implementation of this share repurchase plan has been completed.
Watson Biotech (300142.SZ): Currently, the 13-valent pneumonia conjugate vaccine has been vaccinated in four countries including Morocco
On April 3, GLONGHUI | Watson Biotech (300142.SZ) said on the investor interactive platform that the company's 13-valent pneumonia conjugate vaccine has now been vaccinated in four countries: Morocco, Thailand, Bangladesh and Indonesia.
No Data